SARS-CoV-2 JN.1 variant evasion of IGHV3-53/3-66 B cell germlines.
Humans
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ immunology
COVID-19
/ immunology
Antibodies, Neutralizing
/ immunology
B-Lymphocytes
/ immunology
Antibodies, Viral
/ immunology
Immune Evasion
/ immunology
Antibodies, Monoclonal
/ immunology
Immunoglobulin Heavy Chains
/ genetics
Germ Cells
/ immunology
Journal
Science immunology
ISSN: 2470-9468
Titre abrégé: Sci Immunol
Pays: United States
ID NLM: 101688624
Informations de publication
Date de publication:
09 Aug 2024
09 Aug 2024
Historique:
medline:
9
8
2024
pubmed:
9
8
2024
entrez:
9
8
2024
Statut:
ppublish
Résumé
The severe acute respiratory syndrome coronavirus 2 variant JN.1 recently emerged as the dominant variant despite having only one amino acid change on the spike (S) protein receptor binding domain (RBD) compared with the ancestral BA.2.86, which never represented more than 5% of global variants. To define at the molecular level the JN.1 ability to spread globally, we interrogated a panel of 899 neutralizing human monoclonal antibodies. Our data show that the single leucine-455-to-serine mutation in the JN.1 spike protein RBD unleashed the global spread of JN.1, likely occurring by elimination of more than 70% of the neutralizing antibodies mediated by IGHV3-53/3-66 germlines. However, the resilience of class 3 antibodies with low neutralization potency but strong Fc functions may explain the absence of JN.1 severe disease.
Identifiants
pubmed: 39121195
doi: 10.1126/sciimmunol.adp9279
doi:
Substances chimiques
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Antibodies, Monoclonal
0
Immunoglobulin Heavy Chains
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM